13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
68 檔
11.4%
According to the latest 13F quarterly dataset, Deep Track Capital, LP managed an equity portfolio of $6.9B at the end of Q2 2024, spanning 68 distinct U.S. exchange-listed positions.
During Q2 2024, Deep Track Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | Stock-Healthcare | 5.36% | — | +4.55% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.13% | — | +33.33% | |
| 3 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.45% | -0.55% | +42.01% | |
| 4 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.21% | -0.11% | -12.19% | |
| 5 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 4.16% | — | +6.33% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 4.00% | — | -58.19% | |
| 7 | GH | Guardant Health Inc | Stock-Healthcare | 3.88% | +2.37% | -25.00% | |
| 8 | DVAX | Dynavax Technologies CORP | Stock-Other | 3.65% | — | +19.23% | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.63% | +3.61% | NEW | |
| 10 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.21% | — | +13.99% | |
| 11 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.14% | — | -8.21% | |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 2.86% | -2.98% | EXIT | |
| 13 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.85% | +0.15% | +45.62% | |
| 14 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.60% | +0.09% | — | |
| 15 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.54% | — | +33.84% | |
| 16 | ALKS | Alkermes plc | Stock-Healthcare | 2.52% | +0.98% | — | |
| 17 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.49% | +1.12% | +33.15% | |
| 18 | IMVT | Immunovant Inc | Stock-Other | 2.27% | +0.56% | +484.52% | |
| 19 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 2.11% | — | — | |
| 20 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.92% | — | +3.87% | |
| 21 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.81% | — | — | |
| 22 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.73% | — | +25.49% | |
| 23 | ABVX | Abivax Sa-adr | Stock-Other | 1.65% | — | -2.74% | |
| 24 | GERN | Geron CORP | Stock-Other | 1.65% | -0.77% | EXIT | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.59% | — | — | |
| 26 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.52% | — | — | |
| 27 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.52% | +0.51% | +13.54% | |
| 28 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.34% | — | +18.84% | |
| 29 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.31% | — | -8.44% | |
| 30 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.29% | +0.27% | NEW | |
| 31 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.24% | -0.92% | EXIT | |
| 32 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.23% | — | +44.77% | |
| 33 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.17% | -0.39% | EXIT | |
| 34 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.11% | +0.33% | +2266.89% | |
| 35 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.89% | -0.75% | EXIT | |
| 36 | EDIT | Editas Medicine Inc | Stock-Other | 0.84% | — | +8.55% | |
| 37 | CLYM | Climb Bio Inc | Stock-Other | 0.83% | — | — | |
| 38 | ✓ | Hillevax Inc | Stock-Other | 0.79% | — | -28.76% | |
| 39 | KRRO | Korro Bio Inc | Stock-Other | 0.78% | — | — | |
| 40 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.77% | — | -17.28% | |
| 41 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.66% | — | -2.85% | |
| 42 | ✓ | Engene Holdings Inc | Stock-Other | 0.63% | -0.49% | EXIT | |
| 43 | ALEC | Alector Inc | Stock-Other | 0.63% | — | +22.88% | |
| 44 | ETNBGBP | 89bio Inc | Stock-Other | 0.55% | — | — | |
| 45 | FATE | Fate Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 46 | INO | Inovio Pharmaceuticals Inc | Stock-Other | 0.50% | — | — | |
| 47 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.48% | — | — | |
| 48 | CYBNEUR | Cybin Inc | Stock-Other | 0.47% | — | — | |
| 49 | CNTX | Context Therapeutics Inc | Stock-Other | 0.44% | -0.26% | — | |
| 50 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.41% | — | — |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 68 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AMGN, ARGX, AXSM) accounted for 11.4% of total reported equity market value during Q2 2024.
During Q2 2024, Deep Track Capital, LP's top holdings by market value included AMGN (5.4%)、ARGX (5.1%)、AXSM (4.5%). The largest single position, AMGN, represented 5.4% of total portfolio value.
In Q2 2024, Deep Track Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.